Skip to main content

Table 2 Baseline demographics and patient characteristics (ITT population)

From: Randomized, active-controlled, comparative phase 3 efficacy and safety equivalence trial of Ovaleap® (recombinant human follicle-stimulating hormone) in infertile women using assisted reproduction technology (ART)

Characteristic

Ovaleap® (n = 153)

Gonal-f® (n = 146)

Age, years, mean (SD)

31.6 (3.1)

31.7 (3.2)

Age, n (%)

  

  < 30 years

35 (22.9)

36 (24.7)

 30 to 34 years

93 (60.8)

75 (51.4)

  > 34 years

25 (16.3)

35 (24.0)

Weight, kg, mean (SD)

63.8 (10.2)

63.1 (9.2)

BMI, kg/m2, mean (SD)

22.8 (2.9)

22.6 (2.9)

Smoker, n (%)

18 (11.8)

19 (13.0)

Alcohol consumption, n (%)

33 (21.6)

23 (15.8)

Duration of infertility, in months at baseline, mean (SD)

43.6 (26.2)

46.6 (29.0)

Causes of infertilitya, n (%)

  

 Male factor

86 (56.2)

77 (52.7)

 Idiopathic

39 (25.5)

41 (28.1)

 Tubal factor

26 (17.0)

30 (20.5)

 Endometriosis

10 (6.5)

10 (6.8)

 Other

6 (3.9)

10 (6.8)

Pregnancy history, n (%)

  

 Previous pregnancy

45 (29.4)

51 (34.9)

 Previous miscarriage

22 (14.4)

35 (24.0)

 Previous still birth

4 (2.6)

1 (0.7)

 Previous live birth

27 (17.6)

20 (13.7)

Total ovarian volume, mL

  

 Mean (SD)

19.0 (50.7)

15.5 (11.8)

 Median

12.0

12.6

Basal antral follicles ≥ 5 mm, mean (SD)

n = 153

n = 145

 Right ovary

5.3 (3.4)

5.2 (4.3)

 Left ovary

5.0 (3.2)

4.8 (4.3)

Basal FSH levels, mU/mL, mean (SD)

7.0 (1.6)

7.3 (2.3)

  1. ITT intent-to-treat, SD standard deviation, BMI body mass index, FSH follicle-stimulating hormone
  2. aMultiple causes per patient are possible